{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:58:09Z","timestamp":1791619089128,"version":"4.3.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T00:00:00Z","timestamp":1502668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2018,10]]},"abstract":"\n Purpose:<\/jats:title>\n To evaluate the use of direct-acting oral anticoagulants in patients with cancer and venous thromboembolism (VTE) treated at Ochsner Medical Center with the intent of determining the efficacy and safety of these agents.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Patients were identified by a retrospective data extraction of patients treated at Ochsner Medical Center from January 1, 2013, through December 31, 2015. Patients were included for review if they were \u226518 years of age, with a confirmed diagnosis of VTE and active or history of cancer, and if they received dabigatran, apixaban, rivaroxaban, or edoxaban for at least 6 months. The primary objectives were the rate of recurrence of VTE and the incidence of bleeding at 6 months.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Thirty-seven patients were identified. Twelve patients were diagnosed with PE, 21 with DVT, 3 with DVT and PE, and 1 with DVT and superficial vein thrombosis (SVT). Apixaban was used most often (n = 27). No patients experienced a recurrent DVT or PE at 6 months. Two patients experienced adverse effects during treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n In this single-center, retrospective, observational study in patients with cancer receiving DOAC therapy, there were no episodes of recurrent VTE and only 2 episodes of clinically significant bleeding.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/0897190017722873","type":"journal-article","created":{"date-parts":[[2017,8,14]],"date-time":"2017-08-14T03:58:31Z","timestamp":1502683111000},"page":"441-444","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer"],"prefix":"10.1177","volume":"31","author":[{"given":"Daphne O.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,8,14]]},"reference":[{"key":"bibr1-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1283"},{"key":"bibr2-0897190017722873","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cancer-associated venous thromboembolic disease. Version 1.2015. www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf. Published 2015. Accessed May 26, 2016."},{"key":"bibr3-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025313"},{"key":"bibr4-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"bibr5-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"bibr6-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"bibr7-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"bibr8-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1160\/TH16-08-0615"},{"key":"bibr9-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432504"},{"key":"bibr10-0897190017722873","first-page":"453","volume":"8","author":"Seaman S","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"bibr11-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1177\/1076029616677800"},{"key":"bibr12-0897190017722873","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.12.016"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017722873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190017722873","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017722873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:34:36Z","timestamp":1777509276000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190017722873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,14]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1177\/0897190017722873"],"URL":"https:\/\/doi.org\/10.1177\/0897190017722873","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,14]]}}}